Bensen Daniel's Form 4 filing
Tyra Biosciences, Inc. (TYRA) · filed Jul 3, 2023
- Accession no.
- 0001209191-23-040654
- Filed
- Jul 3, 2023
- Trade date
- Jun 29-Jul 3, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 3 derivative transactions. Open-market sales total $674.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bensen DanielCIK 0001880946 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 29, 2023 | Common Stock | MOption exerciseAcquired | +17,281 | $0.61 | +$10,541.41 | 545,262 | Direct | |
| Jun 29, 2023 | Common Stock | SSaleDisposed | −17,281 | $16.49F2 | −$284,963.69 | 527,981 | Direct | |
| Jun 30, 2023 | Common Stock | MOption exerciseAcquired | +18,819 | $0.61 | +$11,479.59 | 546,800 | Direct | |
| Jun 30, 2023 | Common Stock | SSaleDisposed | −18,819 | $16.97F3 | −$319,358.43 | 527,981 | Direct | |
| Jul 3, 2023 | Common Stock | MOption exerciseAcquired | +4,265 | $0.61 | +$2,601.65 | 532,246 | Direct | |
| Jul 3, 2023 | Common Stock | SSaleDisposed | −3,865 | $16.30F4 | −$62,999.5 | 528,381 | Direct | |
| Jul 3, 2023 | Common Stock | SSaleDisposed | −400 | $17.04F5 | −$6,816 | 527,981 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 29, 2023 | Common Stock | MOption exerciseDisposed | −17,281 | $0.00 | $0 | 164,997 | Direct | |
| Jun 30, 2023 | Common Stock | MOption exerciseDisposed | −18,819 | $0.00 | $0 | 146,178 | Direct | |
| Jul 3, 2023 | Common Stock | MOption exerciseDisposed | −4,265 | $0.00 | $0 | 141,913 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.13 to $17.09. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.45 to $17.14. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16 to $17. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F5
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $17.02 to $17.05. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.